Early Postoperative Circulating miR-483-5p Is a Prognosis Marker for Adrenocortical Cancer
We have previously identified serum miR-483-5p as a preoperative diagnosis and prognosis biomarker for adrenocortical cancer (ACC). Here, we aimed to determine whether circulating miR-483-5p levels measured 3 months post-operatively distinguished patients with good prognosis (no recurrence for at le...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-03-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/12/3/724 |
| _version_ | 1797708259341107200 |
|---|---|
| author | Maurine Oreglia Silviu Sbiera Martin Fassnacht Laurent Guyon Josiane Denis Justine Cristante Olivier Chabre Nadia Cherradi |
| author_facet | Maurine Oreglia Silviu Sbiera Martin Fassnacht Laurent Guyon Josiane Denis Justine Cristante Olivier Chabre Nadia Cherradi |
| author_sort | Maurine Oreglia |
| collection | DOAJ |
| description | We have previously identified serum miR-483-5p as a preoperative diagnosis and prognosis biomarker for adrenocortical cancer (ACC). Here, we aimed to determine whether circulating miR-483-5p levels measured 3 months post-operatively distinguished patients with good prognosis (no recurrence for at least 3 years; NR3yrs) from patients with poor prognosis (recurrence or death within 3 years after surgery; R < 3yrs). We conducted a single-center retrospective analysis using sera from 48 patients with ACC that were initially non-metastatic and treated by surgery. Sera sampled within 3 months after surgery were available in 26 patients. MiR-483-5p absolute circulating levels were measured using quantitative PCR. Thirteen patients showed a recurrence before 3 years (=R < 3yrs). Thirteen patients showed no recurrence within 3 years, including 11 patients with a follow-up longer than 3 years (=NR3yrs). Serum miR-483-5p levels were higher in R < 3yrs than in NR3yrs: 1,541,990 ± 428,377 copies/mL vs. 388,457 ± 62,169 copies/mL (<i>p</i> = 0.002). Receiver operating characteristic analysis showed that a value of 752,898 copies/mL distinguished R < 3yrs from NR3yrs with 61.5% sensitivity (CI 31.6−86.1) and 100% specificity (CI 71.5−100) with an area under the curve of 0.853. Patients with a value below this threshold had a significantly longer recurrence-free and overall survival. In multivariate analysis, miR-483-5p provided the single best prognostic value for recurrence-free survival (RFS) (hazard ratio (HR) for recurrence 5.98, <i>p</i> < 0.011) but not for overall survival. Our study suggests that serum miR-483-5p is a potent early post-operative biomarker for ACC prognosis that might be a better predictor of RFS than currently used markers. |
| first_indexed | 2024-03-12T06:18:42Z |
| format | Article |
| id | doaj.art-5aac4ebc321f41659faa0a25cebba3ab |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-12T06:18:42Z |
| publishDate | 2020-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-5aac4ebc321f41659faa0a25cebba3ab2023-09-03T02:22:26ZengMDPI AGCancers2072-66942020-03-0112372410.3390/cancers12030724cancers12030724Early Postoperative Circulating miR-483-5p Is a Prognosis Marker for Adrenocortical CancerMaurine Oreglia0Silviu Sbiera1Martin Fassnacht2Laurent Guyon3Josiane Denis4Justine Cristante5Olivier Chabre6Nadia Cherradi7Centre Hospitalier Universitaire Grenoble Alpes, Service d’Endocrinologie, F-38000 Grenoble, FranceDepartment of Internal Medicine I, Endocrinology and Diabetes Unit, University Hospital Würzburg, 97080 Würzburg, GermanyDepartment of Internal Medicine I, Endocrinology and Diabetes Unit, University Hospital Würzburg, 97080 Würzburg, GermanyUniv. Grenoble Alpes, INSERM, CEA, IRIG, Biology of Cancer and Infection UMR_S 1036, F-38000 Grenoble, FranceUniv. Grenoble Alpes, INSERM, CEA, IRIG, Biology of Cancer and Infection UMR_S 1036, F-38000 Grenoble, FranceCentre Hospitalier Universitaire Grenoble Alpes, Service d’Endocrinologie, F-38000 Grenoble, FranceCentre Hospitalier Universitaire Grenoble Alpes, Service d’Endocrinologie, F-38000 Grenoble, FranceUniv. Grenoble Alpes, INSERM, CEA, IRIG, Biology of Cancer and Infection UMR_S 1036, F-38000 Grenoble, FranceWe have previously identified serum miR-483-5p as a preoperative diagnosis and prognosis biomarker for adrenocortical cancer (ACC). Here, we aimed to determine whether circulating miR-483-5p levels measured 3 months post-operatively distinguished patients with good prognosis (no recurrence for at least 3 years; NR3yrs) from patients with poor prognosis (recurrence or death within 3 years after surgery; R < 3yrs). We conducted a single-center retrospective analysis using sera from 48 patients with ACC that were initially non-metastatic and treated by surgery. Sera sampled within 3 months after surgery were available in 26 patients. MiR-483-5p absolute circulating levels were measured using quantitative PCR. Thirteen patients showed a recurrence before 3 years (=R < 3yrs). Thirteen patients showed no recurrence within 3 years, including 11 patients with a follow-up longer than 3 years (=NR3yrs). Serum miR-483-5p levels were higher in R < 3yrs than in NR3yrs: 1,541,990 ± 428,377 copies/mL vs. 388,457 ± 62,169 copies/mL (<i>p</i> = 0.002). Receiver operating characteristic analysis showed that a value of 752,898 copies/mL distinguished R < 3yrs from NR3yrs with 61.5% sensitivity (CI 31.6−86.1) and 100% specificity (CI 71.5−100) with an area under the curve of 0.853. Patients with a value below this threshold had a significantly longer recurrence-free and overall survival. In multivariate analysis, miR-483-5p provided the single best prognostic value for recurrence-free survival (RFS) (hazard ratio (HR) for recurrence 5.98, <i>p</i> < 0.011) but not for overall survival. Our study suggests that serum miR-483-5p is a potent early post-operative biomarker for ACC prognosis that might be a better predictor of RFS than currently used markers.https://www.mdpi.com/2072-6694/12/3/724adrenocortical carcinomabiomarkercirculating micrornamir-483-5pearly prognosisrecurrence |
| spellingShingle | Maurine Oreglia Silviu Sbiera Martin Fassnacht Laurent Guyon Josiane Denis Justine Cristante Olivier Chabre Nadia Cherradi Early Postoperative Circulating miR-483-5p Is a Prognosis Marker for Adrenocortical Cancer Cancers adrenocortical carcinoma biomarker circulating microrna mir-483-5p early prognosis recurrence |
| title | Early Postoperative Circulating miR-483-5p Is a Prognosis Marker for Adrenocortical Cancer |
| title_full | Early Postoperative Circulating miR-483-5p Is a Prognosis Marker for Adrenocortical Cancer |
| title_fullStr | Early Postoperative Circulating miR-483-5p Is a Prognosis Marker for Adrenocortical Cancer |
| title_full_unstemmed | Early Postoperative Circulating miR-483-5p Is a Prognosis Marker for Adrenocortical Cancer |
| title_short | Early Postoperative Circulating miR-483-5p Is a Prognosis Marker for Adrenocortical Cancer |
| title_sort | early postoperative circulating mir 483 5p is a prognosis marker for adrenocortical cancer |
| topic | adrenocortical carcinoma biomarker circulating microrna mir-483-5p early prognosis recurrence |
| url | https://www.mdpi.com/2072-6694/12/3/724 |
| work_keys_str_mv | AT maurineoreglia earlypostoperativecirculatingmir4835pisaprognosismarkerforadrenocorticalcancer AT silviusbiera earlypostoperativecirculatingmir4835pisaprognosismarkerforadrenocorticalcancer AT martinfassnacht earlypostoperativecirculatingmir4835pisaprognosismarkerforadrenocorticalcancer AT laurentguyon earlypostoperativecirculatingmir4835pisaprognosismarkerforadrenocorticalcancer AT josianedenis earlypostoperativecirculatingmir4835pisaprognosismarkerforadrenocorticalcancer AT justinecristante earlypostoperativecirculatingmir4835pisaprognosismarkerforadrenocorticalcancer AT olivierchabre earlypostoperativecirculatingmir4835pisaprognosismarkerforadrenocorticalcancer AT nadiacherradi earlypostoperativecirculatingmir4835pisaprognosismarkerforadrenocorticalcancer |